The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
Hay
C R
CR
Manchester Haemophilia Comprehensive Care Centre, University Department of Haematology, Manchester Royal Infirmary, UK. haemophilia@man.ac.uk
Baglin
T P
TP
Collins
P W
PW
Hill
F G
FG
Keeling
D M
DM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood*; D019774:Blood Coagulation Factor Inhibitors / Q000032:analysis*; D002648:Child; D005164:Factor IX / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D005169:Factor VIII / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000276:immunology; D006207:Half-Life; D006467:Hemophilia A / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D002836:Hemophilia B / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D006488:Hemostasis, Surgical; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D019774:Blood Coagulation Factor Inhibitors; D006490:Hemostatics; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX